PF-07258669 + midazolam

PF-07258669 + midazolam is an experimental combination of two drugs: - **PF-07258669** is an orally administered, investigational small molecule developed by Pfizer that has undergone Phase 1 clinical testing for safety, tolerability, and pharmacokinetics in healthy adults. Its detailed mechanism of action has not been publicly disclosed by the manufacturer as of September 2025, but Phase 1 data confirm its rapid absorption and dose-proportional pharmacokinetics at studied doses[2][4]. - **Midazolam** is a benzodiazepine indicated for anesthesia, sedation, and treatment of acute seizures. It is a positive allosteric modulator of the GABA-A receptor, leading to central nervous system depression, sedation, and anticonvulsant effects. It is widely used clinically and functions mainly by enhancing inhibitory neurotransmission[3][5]. The combination is being studied to evaluate potential pharmacokinetic interactions, specifically the effect of PF-07258669 on midazolam metabolism, likely as a probe for CYP3A enzymatic activity[1].